Department of Structural and Functional Biology, Biology Institute, State University of Campinas, Campinas, São Paulo, Brazil.
Faculty of Medical Sciences, Department of Clinical Pathology, State University of Campinas, Campinas, São Paulo, Brazil.
Cell Biol Int. 2018 Jun;42(6):747-753. doi: 10.1002/cbin.10950. Epub 2018 Mar 1.
Cardiovascular diseases are major causes of death worldwide. Beyond the classical cholesterol risk factor, other conditions such as oxidative stress are well documented to promote atherosclerosis. The Mangifera indica L. extract (Vimang®) was reported to present antioxidant and hypocholesterolemic properties. Thus, here we evaluate the effects of Vimang treatment on risk factors of the atherosclerosis prone model of familial hypercholesterolemia, the LDL receptor knockout mice. Mice were treated with Vimang during 2 weeks and were fed a cholesterol-enriched diet during the second week. The Vimang treated mice presented significantly reduced levels of plasma (15%) and liver (20%) cholesterol, increased plasma total antioxidant capacity (10%) and decreased reactive oxygen species (ROS) production by spleen mononuclear cells (50%), P < 0.05 for all. In spite of these benefits, the average size of aortic atherosclerotic lesions stablished in this short experimental period did not change significantly in Vimang treated mice. Therefore, in this study we demonstrated that Vimang has protective effects on systemic and tissue-specific risk factors, but it is not sufficient to promote a reduction in the initial steps of atherosclerosis development. In addition, we disclosed a new antioxidant target of Vimang, the spleen mononuclear cells that might be relevant for more advanced stages of atherosclerosis.
心血管疾病是全球主要的死亡原因。除了经典的胆固醇风险因素外,其他一些情况,如氧化应激,也被充分证明可促进动脉粥样硬化。芒果提取物(Vimang®)具有抗氧化和降胆固醇的特性。因此,我们在此评估 Vimang 治疗对家族性高胆固醇血症易患动脉粥样硬化模型(LDL 受体基因敲除小鼠)的风险因素的影响。小鼠用 Vimang 治疗 2 周,并在第 2 周给予富含胆固醇的饮食。Vimang 治疗的小鼠血浆(15%)和肝脏(20%)胆固醇水平显著降低,血浆总抗氧化能力(10%)增加,脾单核细胞产生的活性氧(ROS)减少(50%),所有这些均有统计学意义(P<0.05)。尽管有这些益处,但在这个短期实验期间,Vimang 治疗的小鼠主动脉粥样硬化病变的平均大小并没有显著改变。因此,在这项研究中,我们证明了 Vimang 对系统性和组织特异性风险因素具有保护作用,但不足以促进动脉粥样硬化发展初始阶段的减少。此外,我们揭示了 Vimang 的一个新的抗氧化靶点,即脾单核细胞,这可能与更晚期的动脉粥样硬化有关。